ArticleYonsei medical journal2007
Species distribution and susceptibility to azole antifungals of Candida bloodstream isolates from eight university hospitals in Korea.
Article in Yonsei medical journal, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Evidence-based guidelines for empirical therapy of neutropenic fever in Korea.The Korean journal of internal medicine · 2011Guideline
- Risk Factors for Mortality inJournal of fungi (Basel, Switzerland) · 2026Article
- Clinical Outcomes ofJournal of fungi (Basel, Switzerland) · 2026Article
- Time to positivity of blood cultures causing candidemia and its relation to mortality.Iranian journal of microbiology · 2024Article
- Nationwide Surveillance of Antifungal Resistance ofJournal of fungi (Basel, Switzerland) · 2022Article
- Time to Detection of Yeast Isolates in Pediatric and Adult Patients with Fungemia and its Relevance to Clinical Profile and Outcome.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2019Article
- In Vitro Susceptibility and Trailing Growth Effect of Clinical Isolates of Candida Species to Azole Drugs.Jundishapur journal of microbiology · 2016Article
- Antifungal susceptibilities of Candida, Cryptococcus neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: data from the SENTRY antifungal surveillance program (2010-2012).The Journal of antibiotics · 2015Article
- Antifungal susceptibility and virulence attributes of bloodstream isolates of Candida from Hong Kong and Finland.Mycopathologia · 2011Article
- An observational study on the epidemiological and mycological profile of Candidemia in ICU patients.Medical science monitor : international medical journal of experimental and clinical research · 2011Article
- Evaluation of antifungal susceptibility testing with microdilution and Etest methods of Candida blood isolates.Mycopathologia · 2011Article
- Comparison of nosocomial candidemia of pediatric and adult cases in 2-years period at a Turkish university hospital.The Eurasian journal of medicine · 2011Article
- Comprehensive analysis of blood culture performed at nine university hospitals in Korea.The Korean journal of laboratory medicine · 2011Article
- Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion.Journal of clinical microbiology · 2010Article
- Candida parapsilosis, an emerging fungal pathogen.Clinical microbiology reviews · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe incidence of Candida bloodstream infections (BSI) has increased over the past two decades. The rank order of occurrence and the susceptibility to antifungals of the various Candida species causing BSI are important factors driving the establishment of empirical treatment protocols; however, very limited multi-institutional data are available on Candida bloodstream isolates in Korea. MATERIALS AND
methodsWe investigated the susceptibility to azole antifungals and species distribution of 143 Candida bloodstream isolates recovered from eight university hospitals over a six-month period. Minimal inhibitory concentrations (MICs) of fluconazole, itraconazole, and voriconazole for each isolate were determined by the broth microdilution method of the Clinical and Laboratory Standards Institute (CLSI).
resultsThe Candida species recovered most frequently from the blood cultures was C. albicans (49%), followed by C. parapsilosis (22%), C. tropicalis (14%), and C. glabrata (11%). The MIC ranges for the Candida isolates were 0.125 to 64 microg/mL for fluconazole, 0.03 to 2 microg/mL for itraconazole, and 0.03 to 1 microg/mL for voriconazole. Overall, resistance to fluconazole was found in only 2% of the Candida isolates (3/143), while the dose-dependent susceptibility was found in 6% (8/143). The resistance and dose-dependent susceptibility of itraconazole were found in 4% (6/143) and 14% (20/143) of the isolates, respectively. All bloodstream isolates were susceptible to voriconazole (MIC, < or = 1 microg/mL).
conclusionOur findings show that C. albicans is the most common cause of Candida-related BSI, followed by C. parapsilosis, and that the rates of resistance to azole antifungals are still low among bloodstream isolates in Korea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.